John Johnson, MD
Family Medicine · Jena, LANPI 1619234945
Payments from drug & device makers
Across 128 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$363
- Pfizer$166
- Takeda Pharmaceuticals U.S.A., Inc.$142
- Bayer$126
- Lilly USA, LLC$123
- Abbott$107
- plus $883 from 21 others
What the payments were for
- Food & beverage$1,88098%
- Education$302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $363 |
| Pfizer | 11 | $166 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $142 |
| Bayer | 8 | $126 |
| Lilly USA, LLC | 8 | $123 |
| Abbott | 6 | $107 |
| Astellas Pharma US Inc | 7 | $104 |
| GSK | 7 | $101 |
| Amgen | 7 | $95 |
| AbbVie(2 entities) | 5 | $94 |
| AstraZeneca | 5 | $68 |
| Boehringer Ingelheim | 4 | $56 |
| Sanofi-aventis U.S. LLC | 4 | $53 |
| Novartis | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 3 | $44 |
| Merck | 3 | $39 |
| Johnson & Johnson | 3 | $39 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Corium, LLC | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Nevro Corp. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $11 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
How this compares
$1,910 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 191 | $181,143 |
| EliquisApixaban | 239 | $151,517 |
| JardianceEmpagliflozin | 155 | $112,959 |
| MounjaroTirzepatide | 60 | $70,163 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $51,459 |
| FarxigaDapagliflozin Propanediol | 62 | $43,037 |
| TrulicityDulaglutide | 35 | $33,306 |
| LinzessLinaclotide | 52 | $32,350 |
| XareltoRivaroxaban | 51 | $32,251 |
| JanuviaSitagliptin Phosphate | 35 | $28,877 |
| RexultiBrexpiprazole | 31 | $26,163 |
| MyrbetriqMirabegron | 52 | $23,162 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 23 | $13,390 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $12,287 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $9,349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $363 | $181,143191 claims |
| PfizerEliquis | $166 | $151,517239 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Synjardy Xr | $56 | $128,926186 claims |
| Lilly USA, LLCMounjaro, Trulicity | $123 | $103,46895 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $101 | $59,13570 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $68 | $55,32480 claims |
| MerckJanuvia, Janumet Xr | $39 | $42,26658 claims |
| AbbVieLinzess | $94 | $32,35052 claims |
| Johnson & JohnsonXarelto | $39 | $32,25151 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $44 | $26,16331 claims |
| Astellas Pharma US IncMyrbetriq | $104 | $23,16252 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $142 | $5,52712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Jena
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
- Clint WilsonBossier City$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.